A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the ...

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...

A produtora do Ozempic, Novo Nordisk, planeja fabricar mais medicamentos para o mercado dos Estados Unidos localmente; a ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

Novo Nordisk (NVO) ended the recent trading session at $75.89, demonstrating a +1.47% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss of ...

FRANKFURT: European shares closed slightly lower on Thursday after US President Donald Trump threatened to impose tariffs on ...

Apollo Global Management, Novo Nordisk A/S, BlackRock, Blackstone, and Prologis are the five Growth stocks to watch today, according to MarketBeat’s stock screener tool. Growth stocks are shares of ...